Takeda Pharmaceutical Company Limited
TKPHF
$28.63
-$1.45-4.81%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 1.87% | 1.10% | -1.33% | -0.76% | -1.23% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.87% | 1.10% | -1.33% | -0.76% | -1.23% |
| Cost of Revenue | 9.65% | 10.12% | 9.13% | 8.51% | -0.24% |
| Gross Profit | -1.83% | -3.00% | -5.96% | -4.86% | -1.68% |
| SG&A Expenses | -0.87% | -1.00% | -2.40% | -1.10% | -1.01% |
| Depreciation & Amortization | 0.18% | -0.61% | -4.44% | -4.67% | -3.11% |
| Other Operating Expenses | 20.62% | -14.61% | 44.49% | 32.28% | -13.04% |
| Total Operating Expenses | 2.97% | 2.66% | 3.86% | 4.30% | -0.35% |
| Operating Income | -6.47% | -8.88% | -33.87% | -32.40% | -7.40% |
| Income Before Tax | 39.74% | 23.08% | -88.07% | -85.15% | -44.11% |
| Income Tax Expenses | 194.75% | -465.40% | -269.48% | -233.15% | -310.08% |
| Earnings from Continuing Operations | 7.55% | 37.69% | -55.22% | -56.56% | -36.59% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -60.63% | -70.50% | -538.31% | -485.59% | -8,693.10% |
| Net Income | 7.52% | 37.67% | -55.27% | -56.59% | -36.63% |
| EBIT | -6.47% | -8.88% | -33.87% | -32.40% | -7.40% |
| EBITDA | -2.80% | -3.57% | -15.52% | -14.30% | -2.79% |
| EPS Basic | 6.34% | 35.82% | -55.73% | -56.87% | -37.01% |
| Normalized Basic EPS | 2.67% | -4.73% | -40.92% | -45.79% | -19.03% |
| EPS Diluted | 5.32% | 35.82% | -55.75% | -56.75% | -36.72% |
| Normalized Diluted EPS | 1.44% | -5.46% | -41.00% | -45.70% | -18.74% |
| Average Basic Shares Outstanding | 1.00% | 0.97% | 0.87% | 0.78% | 0.58% |
| Average Diluted Shares Outstanding | 1.58% | 1.29% | 0.59% | 0.37% | 0.18% |
| Dividend Per Share | -2.89% | -2.89% | -3.60% | -3.60% | -6.68% |
| Payout Ratio | -0.10% | -0.30% | 1.15% | 1.24% | 0.54% |
